Pramlintide, sold under the brand name Symlin, is a synthetic version of amylin, a hormone your pancreas releases alongside insulin every time you eat. It was the first new drug approved to help control blood sugar in people with type 1 diabetes since insulin itself arrived in the 1920s, and it remains the only FDA-approved amylin analog on the market.[7] Because amylin slows the stomach, blunts appetite, and suppresses glucagon, pramlintide also produces modest weight loss, which is why it keeps surfacing in conversations about obesity drugs and why the entire next generation of weight-loss molecules (cagrilintide, petrelintide, and others) is built on the same amylin pathway. This guide covers what pramlintide is, how it works, exact dosing for type 1 and type 2 diabetes, the real-world weight-loss numbers from trials, side effects, and how it stacks up against modern GLP-1 drugs.
🔑 Key Takeaways
- Pramlintide (Symlin) is a synthetic amylin analog, FDA-approved in 2005 as an add-on to mealtime insulin for type 1 and type 2 diabetes, not as a standalone weight-loss drug.[1][7]
- It works through three amylin actions: slowing gastric emptying, increasing satiety in the brain, and suppressing glucagon to lower after-meal glucose.[2][7]
- Dosing is per meal by subcutaneous injection: type 1 starts at 15 mcg and titrates to 30-60 mcg; type 2 starts at 60 mcg and moves to 120 mcg.[1][2]
- Weight loss is modest in diabetes (around 0.5 to 1.6 kg, 1.1 to 3.5 lb), but a 12-month obesity trial showed roughly 6 to 8 kg (13 to 18 lb) at higher doses with lifestyle support.[2][3]
- It carries a boxed warning for severe insulin-induced hypoglycemia and is contraindicated in gastroparesis and hypoglycemia unawareness; it cannot be mixed in the same syringe as insulin.[1]
What Is Pramlintide?
Pramlintide is a man-made analog of human amylin (also called islet amyloid polypeptide). Amylin is a 37-amino-acid hormone co-secreted with insulin from the beta cells of your pancreas in response to meals. In people with type 1 diabetes, amylin is almost completely absent because the beta cells are destroyed; in many people with type 2 diabetes, the amylin response is blunted. Pramlintide replaces that missing meal-time signal.[2][7]
Native human amylin is sticky and aggregates into clumps, which makes it impractical as a drug. Pramlintide solves that by changing 3 of the 37 amino acids (substituting proline residues), which keeps the molecule soluble and stable while preserving its biological activity.[8] It was developed by Amylin Pharmaceuticals, later acquired by AstraZeneca, and approved by the FDA in March 2005.[7][8] It is sold as Symlin and SymlinPen and is given by subcutaneous injection before meals.
Why amylin matters for the obesity drug race
Pramlintide is the proof-of-concept that the amylin pathway can drive both glucose control and weight loss. Every modern amylin-based weight-loss candidate, from once-weekly cagrilintide to next-generation analogs like petrelintide, is essentially trying to do what pramlintide does, but with longer dosing intervals and a smoother side-effect profile. Understanding pramlintide is the fastest way to understand where the amylin class is heading.
How Pramlintide Works: Three Amylin Actions
Insulin and amylin are partners. Insulin handles glucose uptake into cells; amylin manages how fast and how much glucose enters the bloodstream from a meal in the first place. Pramlintide restores that second arm through three mechanisms documented in the FDA label and clinical reviews:[1][2][7]
- Slows gastric emptying. Food leaves the stomach more slowly, so the post-meal glucose spike is flattened and you feel full longer. This is also the source of most of the nausea.
- Suppresses glucagon. It blunts the inappropriate rise in glucagon (the hormone that tells the liver to dump glucose) that occurs after meals in diabetes, reducing hepatic glucose output.
- Promotes satiety. It acts on amylin receptors in the hindbrain (area postrema) to reduce food intake, which is the mechanism behind its appetite suppression and weight effect.
Pramlintide has a short pharmacokinetic profile: maximum concentration is reached roughly 20 minutes after injection and the elimination half-life is about 48 minutes (some reviews cite roughly 29 minutes), which is why it must be dosed at each major meal rather than once daily.[2][7]
Pramlintide Dosing: Type 1 vs Type 2 Diabetes
Pramlintide is dosed in micrograms (mcg) by subcutaneous injection immediately before each major meal (a meal with at least roughly 30 g of carbohydrate or 250 kcal). It uses a U-100 insulin syringe or the SymlinPen, but it must never be combined in the same syringe with insulin because the two have different pH and stability requirements; inject them separately.[1] Dosing differs substantially between the two diabetes types.
| Parameter | Type 1 Diabetes | Type 2 Diabetes |
|---|---|---|
| Starting dose (per meal) | 15 mcg | 60 mcg |
| Titration | Increase in 15 mcg steps (to 30, 45, 60 mcg) | Increase to 120 mcg |
| Maintenance dose (per meal) | 30-60 mcg | 120 mcg |
| When to titrate | After 3-7 days if no significant nausea | After 3-7 days if no significant nausea |
| Mealtime insulin at start | Cut by 50% | Cut by 50% |
At initiation, the mealtime (rapid- or short-acting) insulin dose is reduced by 50% to lower the risk of severe hypoglycemia while you adjust, then re-titrated to target based on glucose monitoring.[1][2] If significant nausea appears, the dose is held at the current step until it settles before going higher. If a patient cannot tolerate the next step after several attempts, treatment is typically stopped.
Practical reference: pramlintide unit math
Because pramlintide doses are tiny and a U-100 insulin syringe is marked in insulin units, prescribers use a conversion: 15 mcg of pramlintide is drawn to the 2.5 unit mark, 30 mcg to the 5 unit mark, 45 mcg to the 7.5 unit mark, 60 mcg to the 10 unit mark, and 120 mcg to the 20 unit mark on a U-100 syringe.[1] The SymlinPen 60 and SymlinPen 120 are designed to remove this math by dosing in fixed mcg increments.
Pramlintide and Weight Loss: What the Data Actually Shows
This is the section most people come for. Pramlintide does cause weight loss, but the magnitude depends heavily on the dose and the population studied.
In diabetes (on-label use)
In the diabetes trials that supported approval, weight loss was modest. Reviews report typical reductions of roughly 0.5 to 1.6 kg (about 1.1 to 3.5 lb) over a year of treatment, with HbA1c falling about 0.2 to 0.4 percentage points in type 1 and 0.4 to 0.6 points in type 2.[2] In a dedicated study of overweight and obese insulin-treated type 2 patients, pramlintide produced a placebo-corrected weight reduction of about 1.8 kg (roughly 4 lb) at 26 weeks, with about 9% of pramlintide patients losing 5% or more of body weight versus 3% on placebo.[9]
In obesity (off-label, higher doses)
When pramlintide was studied specifically for obesity at higher doses, the results were considerably stronger. In a 16-week phase 2 dose-escalation study of 204 obese subjects using up to 240 mcg three times daily, pramlintide produced a placebo-corrected weight loss of about 3.6 kg (roughly 8 lb), or 3.7% of body weight, with about 31% of treated subjects losing at least 5% versus 2% on placebo. The main side effect was mild, transient nausea.[6]
A 12-month trial that combined pramlintide with structured lifestyle intervention in 411 obese subjects went further. The most effective dosing arms achieved 6.1 to 8.0 kg (about 13 to 18 lb) of weight loss, with placebo-corrected reductions of roughly 6 to 7 kg. Between 41% and 65% of subjects on effective doses lost at least 5% of body weight, and around 40 to 43% lost at least 10%, compared with 18% and 12% on placebo. Weight loss was largely sustained over the full year.[3]
| Setting | Dose | Duration | Placebo-corrected weight loss | % losing 5%+ |
|---|---|---|---|---|
| Type 2 diabetes (overweight/obese) | Standard meal dosing | 26 weeks | ~1.8 kg (4 lb) | 9% vs 3% |
| Obesity (phase 2) | Up to 240 mcg 3x/day | 16 weeks | ~3.6 kg (8 lb), 3.7% | 31% vs 2% |
| Obesity + lifestyle | 120 mcg 3x/day to 360 mcg 2x/day | 12 months | ~6-7 kg (13-15 lb) | 41-65% vs 18% |
Despite these obesity results, pramlintide was never FDA-approved for weight loss as a standalone drug. The need to inject before every meal, the nausea ceiling that limited dosing, and the arrival of far more powerful GLP-1 drugs meant the obesity program did not advance to approval. For a broader picture of where injectable amylin and GLP-1 options stand today, see our overview of GLP-1 weight loss and our ranked guide to the best peptides for weight loss.
The combination that hinted at the future: pramlintide plus metreleptin
The most striking obesity data came from pairing pramlintide with metreleptin (a leptin analog). In a 20-week study, the combination produced 12.7% weight loss versus 8.4% with pramlintide alone and 8.2% with metreleptin alone, and weight loss in the combination group kept going without plateauing.[4] This proof that combining two appetite hormones beats either one alone is essentially the playbook now used by combination drugs like CagriSema (cagrilintide plus semaglutide).
Pramlintide vs Modern GLP-1 and Amylin Drugs
Pramlintide and GLP-1 receptor agonists share overlapping effects (both slow gastric emptying and reduce appetite), but they are different hormone classes with very different convenience and potency profiles. The amylin class itself has moved on to once-weekly molecules.
| Drug | Class | Dosing | Typical weight loss | Status |
|---|---|---|---|---|
| Pramlintide (Symlin) | Amylin analog (short-acting) | Before each meal (3x/day) | ~1-4% (diabetes); ~6-7% (obesity trials) | FDA-approved for diabetes |
| Cagrilintide | Amylin analog (long-acting) | Once weekly | ~10-12% alone; ~15% with semaglutide | Phase 3 (CagriSema) |
| Petrelintide | Next-gen amylin analog | Once weekly | Double-digit (early data) | Investigational |
| Semaglutide (Wegovy) | GLP-1 agonist | Once weekly | ~15% | FDA-approved for obesity |
| Tirzepatide (Zepbound) | GLP-1/GIP dual agonist | Once weekly | ~20-22% | FDA-approved for obesity |
The takeaway: pramlintide validated the amylin pathway, but it is dosed three times a day and delivers smaller weight loss than today's once-weekly drugs. The newer amylin analog cagrilintide takes the same biology and stretches it to once-weekly dosing, and a recent obesity pharmacotherapy review notes cagrilintide plus semaglutide reached about 15.6% total body weight loss versus 5.1% for semaglutide alone at 32 weeks in phase 2.[5] If your interest is purely weight loss rather than diabetes glucose control, GLP-1 options like semaglutide and tirzepatide are far more potent. For a head-to-head of how amylin and incretin biology differ, our guide to appetite suppressants puts these mechanisms side by side.
Side Effects and Safety
Pramlintide carries an FDA boxed warning: when used with insulin, it can cause severe hypoglycemia, particularly in type 1 diabetes, and severe lows usually occur within 3 hours of injection. Because of this, it should only be started in patients with good adherence to glucose monitoring and insulin adjustment.[1]
Most common side effects
- Nausea is the dominant side effect and the main reason people stop. In obesity trials, nausea incidence ranged widely (reported anywhere from about 9% up to roughly 29-59% depending on dose and study), but it was usually mild to moderate and faded within the first few weeks as the body adjusts.[2][3]
- Hypoglycemia (when combined with insulin), especially in the first 4 weeks, with risk roughly 2 to 4 times higher than placebo before insulin doses are re-balanced.[2]
- Decreased appetite, vomiting, headache, fatigue, dizziness, and injection-site reactions.[1]
Contraindications and cautions
- Gastroparesis (because pramlintide further slows the stomach).[1]
- Hypoglycemia unawareness (inability to sense low blood sugar).[1]
- Known hypersensitivity to pramlintide or its components.
- Poor adherence to insulin regimen or blood glucose monitoring, or HbA1c above 9%.
On the liver, the NIH LiverTox database rates pramlintide as an unlikely cause of clinically apparent liver injury; there have been no published case reports of hepatotoxicity since approval, and the label does not list liver injury as an adverse event.[8] Pramlintide can also slow the absorption of oral medications, so fast-acting oral drugs (and oral contraceptives, analgesics) should generally be taken at least 1 hour before or 2 hours after a pramlintide injection.[1]
Who pramlintide is and is not for
Good candidate: a person with type 1 or type 2 diabetes already on mealtime insulin whose after-meal glucose stays high despite optimized insulin, who monitors glucose closely, and who wants help with portion control. Poor candidate: someone seeking a convenient standalone weight-loss drug, anyone with gastroparesis or hypoglycemia unawareness, or anyone unwilling to inject before every meal. For weight loss without insulin, a once-weekly GLP-1 or long-acting amylin analog is almost always the better fit.
How Pramlintide Is Prescribed and Stored
Pramlintide is prescription-only in the United States and is dispensed as Symlin vials or as the SymlinPen 60 and SymlinPen 120 prefilled pens. Unopened pens and vials are refrigerated at 36 to 46 degrees F (2 to 8 degrees C). Once in use, an opened pen or vial can be kept refrigerated or at room temperature below 86 degrees F (30 degrees C) and is discarded after 30 days.[1] It is given by subcutaneous injection in the abdomen or thigh (not the arm, because absorption there is too variable), and the injection site is rotated. Pramlintide and insulin are injected at separate sites and never mixed in one syringe.[1]
Frequently Asked Questions
The Bottom Line
Pramlintide is a foundational drug: the first and still only FDA-approved amylin analog, used to sharpen blood-sugar control in people with diabetes who take mealtime insulin. Its weight-loss effect is real but modest at approved doses and stronger at the higher doses studied in obesity, and its requirement for pre-meal injection plus a nausea ceiling kept it from becoming a weight-loss mainstay. Its real legacy is the science it proved: that hitting the amylin pathway, especially in combination with other appetite hormones, drives meaningful weight loss. That insight is now powering the once-weekly amylin analogs and combination drugs shaping the next chapter of obesity treatment.
References
- FDA. SYMLIN (pramlintide acetate) injection, Prescribing Information (boxed warning, indications, dosing, contraindications, adverse reactions).
- Ryan G, et al. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. PMC2761191.
- Smith SR, et al. Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity. Diabetes Care (PMC2518351).
- Ravussin E, et al. Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy. PMC2754219.
- Pharmacotherapy for Obesity: Recent Updates (review of amylin analogs and cagrilintide/CagriSema). PMC12456317.
- Aronne L, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2 dose-escalation study. PubMed 17504894.
- Pramlintide overview (history, FDA 2005 approval, amylin mechanism, half-life).
- NIH LiverTox. Pramlintide (mechanism, 3 of 37 amino-acid substitution, hepatotoxicity assessment).
- Hollander P, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. PubMed 15090634.